A multi-centre, multinational, randomized, double-blind, placebo controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 on exercise capacity in subjects with chronic obstructive pulmonary disease

Trial Profile

A multi-centre, multinational, randomized, double-blind, placebo controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 on exercise capacity in subjects with chronic obstructive pulmonary disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Gisadenafil (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2006 Status change
    • 24 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top